Glycoengineered type II anti-CD20 monoclonal antibody that depletes B cells via direct cell death and antibody-dependent cytotoxicity/phagocytosis (ADCC/ADCP).
Glycoengineered type II anti-CD20 IgG1 monoclonal antibody that binds CD20 on B cells and depletes them through enhanced Fc gamma receptor III (FcγRIII)-mediated ADCC/ADCP and direct, caspase-independent cell death.
NO
INDIRECT
Obinutuzumab binds CD20 on B cells; its Fc engages CD16a (Fc gamma receptor IIIa) on NK cells/macrophages to trigger ADCC/ADCP, killing CD20+ target cells, not the CD16a-expressing effector cells.
Autologous chimeric antigen receptor (CAR) T-cell therapy targeting glypican-3 (GPC3) on hepatocellular carcinoma; patient T cells are engineered to express an anti-GPC3 CAR that, upon antigen engagement, activates T cells and induces perforin/granzyme-mediated cytotoxicity against GPC3-positive tumor cells.
Autologous T cells engineered to express an anti-GPC3 chimeric antigen receptor; binding to GPC3 on hepatocellular carcinoma cells triggers CAR signaling, T-cell activation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of GPC3-positive tumor cells.
YES
DIRECT
Anti-GPC3 CAR T cells bind GPC3 on target cells, activate, and kill them via perforin/granzyme-mediated cytolysis (and death-receptor pathways).
Monoclonal IgG1 antibody against HER2 that blocks receptor activation/dimerization and induces antibody‑dependent cellular cytotoxicity (ADCC).
Humanized IgG1 monoclonal antibody against HER2 (ERBB2) that binds the receptor’s extracellular domain, blocks activation/dimerization and downstream PI3K/AKT and MAPK signaling, and induces antibody-dependent cellular cytotoxicity (ADCC) against HER2-overexpressing tumor cells.
YES
DIRECT
Fc-mediated ADCC: trastuzumab binds HER2 on tumor cells and engages Fcγ receptor–bearing immune cells (e.g., NK cells) to kill the target cell; it also blocks HER2 signaling, which can promote apoptosis.
Afucosylated anti–IL-5Rα monoclonal antibody that induces ADCC to deplete eosinophils and basophils.
Afucosylated humanized monoclonal antibody targeting IL-5 receptor alpha on eosinophils and basophils; binding enhances Fc gamma RIIIa engagement and triggers antibody-dependent cellular cytotoxicity to deplete IL-5Ralpha-expressing cells and reduce type 2 inflammation.
YES
DIRECT
Afucosylated anti–IL-5Rα antibody opsonizes IL-5Rα+ cells and engages FcγRIIIa on NK cells to trigger potent ADCC, leading to perforin/granzyme-mediated apoptosis of eosinophils and basophils.
Chimeric anti-CD20 monoclonal antibody (brand: MabThera) given IV (1 g on days 0 and 15) to deplete CD20+ B cells via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby reducing autoantibody/immune-complex formation, antigen presentation, and B-cell–derived cytokines in refractory chronic hypersensitivity pneumonitis.
Chimeric anti-CD20 monoclonal antibody that binds CD20 on pre-B and mature B lymphocytes and depletes them via complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity, and apoptosis, thereby reducing B cell–mediated autoantibody production, immune complex formation, antigen presentation, and cytokine release.
YES
DIRECT
Rituximab binds CD20 on B cells and induces complement-dependent cytotoxicity and Fc-mediated ADCC by NK/macrophages, and can trigger apoptosis, leading to direct killing of CD20+ cells.